nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—NQO2—breast cancer	0.352	0.911	CbGaD
Dabigatran etexilate—CES2—Irinotecan—breast cancer	0.111	0.301	CbGbCtD
Dabigatran etexilate—CES1—Capecitabine—breast cancer	0.0621	0.169	CbGbCtD
Dabigatran etexilate—CES1—Tamoxifen—breast cancer	0.05	0.136	CbGbCtD
Dabigatran etexilate—CES1—Irinotecan—breast cancer	0.0384	0.104	CbGbCtD
Dabigatran etexilate—ABCB1—breast cancer	0.0342	0.0885	CbGaD
Dabigatran etexilate—UGT1A9—Irinotecan—breast cancer	0.0233	0.0634	CbGbCtD
Dabigatran etexilate—UGT2B7—Epirubicin—breast cancer	0.0227	0.0617	CbGbCtD
Dabigatran etexilate—ABCB1—Toremifene—breast cancer	0.0135	0.0367	CbGbCtD
Dabigatran etexilate—ABCB1—Lapatinib—breast cancer	0.00983	0.0267	CbGbCtD
Dabigatran etexilate—ABCB1—Vinorelbine—breast cancer	0.00545	0.0148	CbGbCtD
Dabigatran etexilate—ABCB1—Tamoxifen—breast cancer	0.00492	0.0134	CbGbCtD
Dabigatran etexilate—ABCB1—Mitoxantrone—breast cancer	0.0048	0.0131	CbGbCtD
Dabigatran etexilate—ABCB1—Gemcitabine—breast cancer	0.00424	0.0115	CbGbCtD
Dabigatran etexilate—ABCB1—Paclitaxel—breast cancer	0.00383	0.0104	CbGbCtD
Dabigatran etexilate—ABCB1—Irinotecan—breast cancer	0.00378	0.0103	CbGbCtD
Dabigatran etexilate—ABCB1—Vinblastine—breast cancer	0.00336	0.00914	CbGbCtD
Dabigatran etexilate—ABCB1—Docetaxel—breast cancer	0.00277	0.00753	CbGbCtD
Dabigatran etexilate—UGT2B15—mammary gland—breast cancer	0.00266	0.0786	CbGeAlD
Dabigatran etexilate—ABCB1—Doxorubicin—breast cancer	0.00206	0.00562	CbGbCtD
Dabigatran etexilate—ABCB1—Methotrexate—breast cancer	0.002	0.00544	CbGbCtD
Dabigatran etexilate—CES2—mammary gland—breast cancer	0.00163	0.048	CbGeAlD
Dabigatran etexilate—F2—mammary gland—breast cancer	0.00146	0.0431	CbGeAlD
Dabigatran etexilate—CES2—nipple—breast cancer	0.00135	0.0397	CbGeAlD
Dabigatran etexilate—NQO2—nipple—breast cancer	0.0012	0.0355	CbGeAlD
Dabigatran etexilate—UGT2B15—female reproductive system—breast cancer	0.0011	0.0325	CbGeAlD
Dabigatran etexilate—UGT2B15—endocrine gland—breast cancer	0.000933	0.0275	CbGeAlD
Dabigatran etexilate—CES2—skin of body—breast cancer	0.000862	0.0254	CbGeAlD
Dabigatran etexilate—F2—epithelium—breast cancer	0.000813	0.024	CbGeAlD
Dabigatran etexilate—CES2—endometrium—breast cancer	0.000813	0.024	CbGeAlD
Dabigatran etexilate—CES2—uterus—breast cancer	0.000749	0.0221	CbGeAlD
Dabigatran etexilate—CES2—pituitary gland—breast cancer	0.000736	0.0217	CbGeAlD
Dabigatran etexilate—CES2—adipose tissue—breast cancer	0.000733	0.0216	CbGeAlD
Dabigatran etexilate—NQO2—endometrium—breast cancer	0.000726	0.0214	CbGeAlD
Dabigatran etexilate—UGT1A9—endocrine gland—breast cancer	0.000707	0.0209	CbGeAlD
Dabigatran etexilate—UGT2B7—female reproductive system—breast cancer	0.000673	0.0199	CbGeAlD
Dabigatran etexilate—CES2—female reproductive system—breast cancer	0.000673	0.0199	CbGeAlD
Dabigatran etexilate—NQO2—uterus—breast cancer	0.000669	0.0198	CbGeAlD
Dabigatran etexilate—NQO2—pituitary gland—breast cancer	0.000657	0.0194	CbGeAlD
Dabigatran etexilate—CES2—adrenal gland—breast cancer	0.000657	0.0194	CbGeAlD
Dabigatran etexilate—NQO2—adipose tissue—breast cancer	0.000655	0.0193	CbGeAlD
Dabigatran etexilate—CES2—bone marrow—breast cancer	0.000636	0.0188	CbGeAlD
Dabigatran etexilate—CES2—female gonad—breast cancer	0.000613	0.0181	CbGeAlD
Dabigatran etexilate—F2—female reproductive system—breast cancer	0.000604	0.0178	CbGeAlD
Dabigatran etexilate—CES1—adipose tissue—breast cancer	0.000603	0.0178	CbGeAlD
Dabigatran etexilate—NQO2—female reproductive system—breast cancer	0.000602	0.0178	CbGeAlD
Dabigatran etexilate—F2—adrenal gland—breast cancer	0.000589	0.0174	CbGeAlD
Dabigatran etexilate—NQO2—adrenal gland—breast cancer	0.000587	0.0173	CbGeAlD
Dabigatran etexilate—F2—bone marrow—breast cancer	0.00057	0.0168	CbGeAlD
Dabigatran etexilate—CES2—endocrine gland—breast cancer	0.00057	0.0168	CbGeAlD
Dabigatran etexilate—UGT2B7—endocrine gland—breast cancer	0.00057	0.0168	CbGeAlD
Dabigatran etexilate—NQO2—bone marrow—breast cancer	0.000568	0.0168	CbGeAlD
Dabigatran etexilate—CES1—female reproductive system—breast cancer	0.000554	0.0164	CbGeAlD
Dabigatran etexilate—F2—female gonad—breast cancer	0.00055	0.0162	CbGeAlD
Dabigatran etexilate—NQO2—female gonad—breast cancer	0.000547	0.0162	CbGeAlD
Dabigatran etexilate—CES1—adrenal gland—breast cancer	0.000541	0.016	CbGeAlD
Dabigatran etexilate—F2—endocrine gland—breast cancer	0.000511	0.0151	CbGeAlD
Dabigatran etexilate—NQO2—endocrine gland—breast cancer	0.000509	0.015	CbGeAlD
Dabigatran etexilate—CES1—female gonad—breast cancer	0.000505	0.0149	CbGeAlD
Dabigatran etexilate—CES1—endocrine gland—breast cancer	0.000469	0.0138	CbGeAlD
Dabigatran etexilate—CES2—lymph node—breast cancer	0.000394	0.0116	CbGeAlD
Dabigatran etexilate—NQO2—lymph node—breast cancer	0.000352	0.0104	CbGeAlD
Dabigatran etexilate—CES1—lymph node—breast cancer	0.000324	0.00957	CbGeAlD
Dabigatran etexilate—ABCB1—embryo—breast cancer	0.000214	0.00632	CbGeAlD
Dabigatran etexilate—ABCB1—epithelium—breast cancer	0.000175	0.00516	CbGeAlD
Dabigatran etexilate—ABCB1—endometrium—breast cancer	0.000157	0.00463	CbGeAlD
Dabigatran etexilate—ABCB1—uterus—breast cancer	0.000144	0.00426	CbGeAlD
Dabigatran etexilate—ABCB1—pituitary gland—breast cancer	0.000142	0.00419	CbGeAlD
Dabigatran etexilate—ABCB1—adipose tissue—breast cancer	0.000141	0.00417	CbGeAlD
Dabigatran etexilate—ABCB1—female reproductive system—breast cancer	0.00013	0.00383	CbGeAlD
Dabigatran etexilate—ABCB1—adrenal gland—breast cancer	0.000127	0.00374	CbGeAlD
Dabigatran etexilate—ABCB1—bone marrow—breast cancer	0.000123	0.00362	CbGeAlD
Dabigatran etexilate—ABCB1—female gonad—breast cancer	0.000118	0.00349	CbGeAlD
Dabigatran etexilate—ABCB1—endocrine gland—breast cancer	0.00011	0.00324	CbGeAlD
Dabigatran etexilate—ABCB1—lymph node—breast cancer	7.6e-05	0.00224	CbGeAlD
Dabigatran etexilate—Urinary tract infection—Epirubicin—breast cancer	3.42e-05	0.000275	CcSEcCtD
Dabigatran etexilate—Hypertension—Capecitabine—breast cancer	3.4e-05	0.000274	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Fluorouracil—breast cancer	3.39e-05	0.000273	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Doxorubicin—breast cancer	3.39e-05	0.000273	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Methotrexate—breast cancer	3.39e-05	0.000273	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Paclitaxel—breast cancer	3.39e-05	0.000272	CcSEcCtD
Dabigatran etexilate—Fatigue—Paclitaxel—breast cancer	3.38e-05	0.000272	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Methotrexate—breast cancer	3.37e-05	0.000271	CcSEcCtD
Dabigatran etexilate—Asthenia—Gemcitabine—breast cancer	3.36e-05	0.00027	CcSEcCtD
Dabigatran etexilate—Arthralgia—Capecitabine—breast cancer	3.36e-05	0.00027	CcSEcCtD
Dabigatran etexilate—Chest pain—Capecitabine—breast cancer	3.36e-05	0.00027	CcSEcCtD
Dabigatran etexilate—Constipation—Paclitaxel—breast cancer	3.35e-05	0.00027	CcSEcCtD
Dabigatran etexilate—Haematuria—Epirubicin—breast cancer	3.35e-05	0.000269	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	3.33e-05	0.000268	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Methotrexate—breast cancer	3.33e-05	0.000268	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Epirubicin—breast cancer	3.32e-05	0.000267	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Docetaxel—breast cancer	3.32e-05	0.000267	CcSEcCtD
Dabigatran etexilate—Epistaxis—Epirubicin—breast cancer	3.32e-05	0.000267	CcSEcCtD
Dabigatran etexilate—Pruritus—Gemcitabine—breast cancer	3.31e-05	0.000266	CcSEcCtD
Dabigatran etexilate—Nausea—Thiotepa—breast cancer	3.31e-05	0.000266	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Methotrexate—breast cancer	3.31e-05	0.000266	CcSEcCtD
Dabigatran etexilate—Infection—Docetaxel—breast cancer	3.3e-05	0.000266	CcSEcCtD
Dabigatran etexilate—Sinusitis—Epirubicin—breast cancer	3.3e-05	0.000265	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Irinotecan—breast cancer	3.29e-05	0.000265	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Mitoxantrone—breast cancer	3.29e-05	0.000265	CcSEcCtD
Dabigatran etexilate—Pneumonia—Doxorubicin—breast cancer	3.27e-05	0.000263	CcSEcCtD
Dabigatran etexilate—Shock—Docetaxel—breast cancer	3.27e-05	0.000263	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Docetaxel—breast cancer	3.26e-05	0.000262	CcSEcCtD
Dabigatran etexilate—Pruritus—Fluorouracil—breast cancer	3.26e-05	0.000262	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Docetaxel—breast cancer	3.25e-05	0.000262	CcSEcCtD
Dabigatran etexilate—Infestation—Doxorubicin—breast cancer	3.25e-05	0.000262	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Doxorubicin—breast cancer	3.25e-05	0.000262	CcSEcCtD
Dabigatran etexilate—Skin disorder—Docetaxel—breast cancer	3.23e-05	0.00026	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Paclitaxel—breast cancer	3.21e-05	0.000258	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Gemcitabine—breast cancer	3.2e-05	0.000258	CcSEcCtD
Dabigatran etexilate—Infection—Capecitabine—breast cancer	3.2e-05	0.000257	CcSEcCtD
Dabigatran etexilate—Dizziness—Irinotecan—breast cancer	3.18e-05	0.000256	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Epirubicin—breast cancer	3.17e-05	0.000255	CcSEcCtD
Dabigatran etexilate—Shock—Capecitabine—breast cancer	3.17e-05	0.000255	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Doxorubicin—breast cancer	3.16e-05	0.000254	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Capecitabine—breast cancer	3.16e-05	0.000254	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Epirubicin—breast cancer	3.16e-05	0.000254	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Fluorouracil—breast cancer	3.15e-05	0.000253	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Capecitabine—breast cancer	3.15e-05	0.000253	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Methotrexate—breast cancer	3.13e-05	0.000252	CcSEcCtD
Dabigatran etexilate—Skin disorder—Capecitabine—breast cancer	3.13e-05	0.000251	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Epirubicin—breast cancer	3.12e-05	0.000251	CcSEcCtD
Dabigatran etexilate—Urticaria—Paclitaxel—breast cancer	3.11e-05	0.00025	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Epirubicin—breast cancer	3.11e-05	0.00025	CcSEcCtD
Dabigatran etexilate—Hypotension—Docetaxel—breast cancer	3.11e-05	0.00025	CcSEcCtD
Dabigatran etexilate—Haematuria—Doxorubicin—breast cancer	3.1e-05	0.000249	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Epirubicin—breast cancer	3.1e-05	0.000249	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Paclitaxel—breast cancer	3.1e-05	0.000249	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Epirubicin—breast cancer	3.09e-05	0.000249	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Doxorubicin—breast cancer	3.08e-05	0.000247	CcSEcCtD
Dabigatran etexilate—Epistaxis—Doxorubicin—breast cancer	3.07e-05	0.000247	CcSEcCtD
Dabigatran etexilate—Angiopathy—Methotrexate—breast cancer	3.06e-05	0.000246	CcSEcCtD
Dabigatran etexilate—Vomiting—Irinotecan—breast cancer	3.06e-05	0.000246	CcSEcCtD
Dabigatran etexilate—Vomiting—Mitoxantrone—breast cancer	3.06e-05	0.000246	CcSEcCtD
Dabigatran etexilate—Sinusitis—Doxorubicin—breast cancer	3.05e-05	0.000245	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Methotrexate—breast cancer	3.05e-05	0.000245	CcSEcCtD
Dabigatran etexilate—Dizziness—Fluorouracil—breast cancer	3.04e-05	0.000245	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Methotrexate—breast cancer	3.04e-05	0.000244	CcSEcCtD
Dabigatran etexilate—Rash—Irinotecan—breast cancer	3.03e-05	0.000244	CcSEcCtD
Dabigatran etexilate—Rash—Mitoxantrone—breast cancer	3.03e-05	0.000244	CcSEcCtD
Dabigatran etexilate—Dermatitis—Irinotecan—breast cancer	3.03e-05	0.000244	CcSEcCtD
Dabigatran etexilate—Dermatitis—Mitoxantrone—breast cancer	3.03e-05	0.000244	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Docetaxel—breast cancer	3.03e-05	0.000243	CcSEcCtD
Dabigatran etexilate—Headache—Mitoxantrone—breast cancer	3.01e-05	0.000242	CcSEcCtD
Dabigatran etexilate—Headache—Irinotecan—breast cancer	3.01e-05	0.000242	CcSEcCtD
Dabigatran etexilate—Hypotension—Capecitabine—breast cancer	3.01e-05	0.000242	CcSEcCtD
Dabigatran etexilate—Vomiting—Gemcitabine—breast cancer	2.98e-05	0.000239	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Docetaxel—breast cancer	2.96e-05	0.000238	CcSEcCtD
Dabigatran etexilate—Rash—Gemcitabine—breast cancer	2.95e-05	0.000237	CcSEcCtD
Dabigatran etexilate—Dermatitis—Gemcitabine—breast cancer	2.95e-05	0.000237	CcSEcCtD
Dabigatran etexilate—Malnutrition—Methotrexate—breast cancer	2.93e-05	0.000236	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Doxorubicin—breast cancer	2.93e-05	0.000236	CcSEcCtD
Dabigatran etexilate—Headache—Gemcitabine—breast cancer	2.93e-05	0.000236	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Capecitabine—breast cancer	2.93e-05	0.000236	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Epirubicin—breast cancer	2.93e-05	0.000235	CcSEcCtD
Dabigatran etexilate—Vomiting—Fluorouracil—breast cancer	2.93e-05	0.000235	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Docetaxel—breast cancer	2.93e-05	0.000235	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Doxorubicin—breast cancer	2.92e-05	0.000235	CcSEcCtD
Dabigatran etexilate—Rash—Fluorouracil—breast cancer	2.9e-05	0.000233	CcSEcCtD
Dabigatran etexilate—Dermatitis—Fluorouracil—breast cancer	2.9e-05	0.000233	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Paclitaxel—breast cancer	2.89e-05	0.000232	CcSEcCtD
Dabigatran etexilate—Headache—Fluorouracil—breast cancer	2.88e-05	0.000232	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Doxorubicin—breast cancer	2.88e-05	0.000232	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Doxorubicin—breast cancer	2.88e-05	0.000231	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Docetaxel—breast cancer	2.87e-05	0.000231	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Doxorubicin—breast cancer	2.87e-05	0.000231	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Capecitabine—breast cancer	2.87e-05	0.000231	CcSEcCtD
Dabigatran etexilate—Fatigue—Docetaxel—breast cancer	2.87e-05	0.00023	CcSEcCtD
Dabigatran etexilate—Angiopathy—Epirubicin—breast cancer	2.86e-05	0.00023	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Doxorubicin—breast cancer	2.86e-05	0.00023	CcSEcCtD
Dabigatran etexilate—Nausea—Irinotecan—breast cancer	2.86e-05	0.00023	CcSEcCtD
Dabigatran etexilate—Nausea—Mitoxantrone—breast cancer	2.86e-05	0.00023	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Epirubicin—breast cancer	2.85e-05	0.000229	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Epirubicin—breast cancer	2.84e-05	0.000229	CcSEcCtD
Dabigatran etexilate—Constipation—Docetaxel—breast cancer	2.84e-05	0.000229	CcSEcCtD
Dabigatran etexilate—Back pain—Methotrexate—breast cancer	2.84e-05	0.000228	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Capecitabine—breast cancer	2.83e-05	0.000228	CcSEcCtD
Dabigatran etexilate—Asthenia—Paclitaxel—breast cancer	2.81e-05	0.000226	CcSEcCtD
Dabigatran etexilate—Nausea—Gemcitabine—breast cancer	2.78e-05	0.000224	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Capecitabine—breast cancer	2.78e-05	0.000223	CcSEcCtD
Dabigatran etexilate—Fatigue—Capecitabine—breast cancer	2.77e-05	0.000223	CcSEcCtD
Dabigatran etexilate—Pruritus—Paclitaxel—breast cancer	2.77e-05	0.000223	CcSEcCtD
Dabigatran etexilate—Constipation—Capecitabine—breast cancer	2.75e-05	0.000221	CcSEcCtD
Dabigatran etexilate—Malnutrition—Epirubicin—breast cancer	2.75e-05	0.000221	CcSEcCtD
Dabigatran etexilate—Nausea—Fluorouracil—breast cancer	2.74e-05	0.00022	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Docetaxel—breast cancer	2.72e-05	0.000219	CcSEcCtD
Dabigatran etexilate—Anaemia—Methotrexate—breast cancer	2.71e-05	0.000218	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Doxorubicin—breast cancer	2.71e-05	0.000218	CcSEcCtD
Dabigatran etexilate—Flatulence—Epirubicin—breast cancer	2.71e-05	0.000218	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Paclitaxel—breast cancer	2.68e-05	0.000216	CcSEcCtD
Dabigatran etexilate—Back pain—Epirubicin—breast cancer	2.66e-05	0.000214	CcSEcCtD
Dabigatran etexilate—Angiopathy—Doxorubicin—breast cancer	2.65e-05	0.000213	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Doxorubicin—breast cancer	2.64e-05	0.000212	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Capecitabine—breast cancer	2.63e-05	0.000212	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Doxorubicin—breast cancer	2.63e-05	0.000212	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Docetaxel—breast cancer	2.63e-05	0.000211	CcSEcCtD
Dabigatran etexilate—Dizziness—Paclitaxel—breast cancer	2.59e-05	0.000209	CcSEcCtD
Dabigatran etexilate—Cough—Methotrexate—breast cancer	2.56e-05	0.000206	CcSEcCtD
Dabigatran etexilate—Urticaria—Capecitabine—breast cancer	2.56e-05	0.000206	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Capecitabine—breast cancer	2.54e-05	0.000205	CcSEcCtD
Dabigatran etexilate—Malnutrition—Doxorubicin—breast cancer	2.54e-05	0.000204	CcSEcCtD
Dabigatran etexilate—Anaemia—Epirubicin—breast cancer	2.54e-05	0.000204	CcSEcCtD
Dabigatran etexilate—Flatulence—Doxorubicin—breast cancer	2.5e-05	0.000201	CcSEcCtD
Dabigatran etexilate—Chest pain—Methotrexate—breast cancer	2.5e-05	0.000201	CcSEcCtD
Dabigatran etexilate—Arthralgia—Methotrexate—breast cancer	2.5e-05	0.000201	CcSEcCtD
Dabigatran etexilate—Vomiting—Paclitaxel—breast cancer	2.49e-05	0.0002	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	2.48e-05	0.0002	CcSEcCtD
Dabigatran etexilate—Rash—Paclitaxel—breast cancer	2.47e-05	0.000199	CcSEcCtD
Dabigatran etexilate—Dermatitis—Paclitaxel—breast cancer	2.47e-05	0.000199	CcSEcCtD
Dabigatran etexilate—Syncope—Epirubicin—breast cancer	2.46e-05	0.000198	CcSEcCtD
Dabigatran etexilate—Back pain—Doxorubicin—breast cancer	2.46e-05	0.000198	CcSEcCtD
Dabigatran etexilate—Headache—Paclitaxel—breast cancer	2.46e-05	0.000198	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Docetaxel—breast cancer	2.45e-05	0.000197	CcSEcCtD
Dabigatran etexilate—Palpitations—Epirubicin—breast cancer	2.43e-05	0.000195	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Epirubicin—breast cancer	2.41e-05	0.000194	CcSEcCtD
Dabigatran etexilate—Cough—Epirubicin—breast cancer	2.4e-05	0.000193	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Methotrexate—breast cancer	2.4e-05	0.000193	CcSEcCtD
Dabigatran etexilate—Asthenia—Docetaxel—breast cancer	2.38e-05	0.000192	CcSEcCtD
Dabigatran etexilate—Infection—Methotrexate—breast cancer	2.38e-05	0.000191	CcSEcCtD
Dabigatran etexilate—Hypertension—Epirubicin—breast cancer	2.37e-05	0.000191	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Capecitabine—breast cancer	2.37e-05	0.000191	CcSEcCtD
Dabigatran etexilate—Pruritus—Docetaxel—breast cancer	2.35e-05	0.000189	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Methotrexate—breast cancer	2.35e-05	0.000189	CcSEcCtD
Dabigatran etexilate—Anaemia—Doxorubicin—breast cancer	2.35e-05	0.000189	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Methotrexate—breast cancer	2.35e-05	0.000189	CcSEcCtD
Dabigatran etexilate—Arthralgia—Epirubicin—breast cancer	2.34e-05	0.000188	CcSEcCtD
Dabigatran etexilate—Chest pain—Epirubicin—breast cancer	2.34e-05	0.000188	CcSEcCtD
Dabigatran etexilate—Nausea—Paclitaxel—breast cancer	2.33e-05	0.000187	CcSEcCtD
Dabigatran etexilate—Skin disorder—Methotrexate—breast cancer	2.33e-05	0.000187	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	2.32e-05	0.000187	CcSEcCtD
Dabigatran etexilate—Asthenia—Capecitabine—breast cancer	2.31e-05	0.000186	CcSEcCtD
Dabigatran etexilate—Syncope—Doxorubicin—breast cancer	2.28e-05	0.000183	CcSEcCtD
Dabigatran etexilate—Pruritus—Capecitabine—breast cancer	2.28e-05	0.000183	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Docetaxel—breast cancer	2.27e-05	0.000183	CcSEcCtD
Dabigatran etexilate—Palpitations—Doxorubicin—breast cancer	2.25e-05	0.000181	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Epirubicin—breast cancer	2.24e-05	0.00018	CcSEcCtD
Dabigatran etexilate—Hypotension—Methotrexate—breast cancer	2.24e-05	0.00018	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Doxorubicin—breast cancer	2.23e-05	0.00018	CcSEcCtD
Dabigatran etexilate—Infection—Epirubicin—breast cancer	2.23e-05	0.000179	CcSEcCtD
Dabigatran etexilate—Cough—Doxorubicin—breast cancer	2.22e-05	0.000178	CcSEcCtD
Dabigatran etexilate—Shock—Epirubicin—breast cancer	2.21e-05	0.000177	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Capecitabine—breast cancer	2.2e-05	0.000177	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Epirubicin—breast cancer	2.2e-05	0.000177	CcSEcCtD
Dabigatran etexilate—Dizziness—Docetaxel—breast cancer	2.2e-05	0.000177	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Epirubicin—breast cancer	2.19e-05	0.000176	CcSEcCtD
Dabigatran etexilate—Hypertension—Doxorubicin—breast cancer	2.19e-05	0.000176	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Methotrexate—breast cancer	2.18e-05	0.000175	CcSEcCtD
Dabigatran etexilate—Skin disorder—Epirubicin—breast cancer	2.18e-05	0.000175	CcSEcCtD
Dabigatran etexilate—Arthralgia—Doxorubicin—breast cancer	2.16e-05	0.000174	CcSEcCtD
Dabigatran etexilate—Chest pain—Doxorubicin—breast cancer	2.16e-05	0.000174	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	2.15e-05	0.000173	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Methotrexate—breast cancer	2.14e-05	0.000172	CcSEcCtD
Dabigatran etexilate—Dizziness—Capecitabine—breast cancer	2.13e-05	0.000171	CcSEcCtD
Dabigatran etexilate—Vomiting—Docetaxel—breast cancer	2.11e-05	0.00017	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Methotrexate—breast cancer	2.11e-05	0.00017	CcSEcCtD
Dabigatran etexilate—Rash—Docetaxel—breast cancer	2.1e-05	0.000169	CcSEcCtD
Dabigatran etexilate—Hypotension—Epirubicin—breast cancer	2.09e-05	0.000168	CcSEcCtD
Dabigatran etexilate—Dermatitis—Docetaxel—breast cancer	2.09e-05	0.000168	CcSEcCtD
Dabigatran etexilate—Headache—Docetaxel—breast cancer	2.08e-05	0.000167	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Doxorubicin—breast cancer	2.07e-05	0.000167	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Methotrexate—breast cancer	2.07e-05	0.000166	CcSEcCtD
Dabigatran etexilate—Fatigue—Methotrexate—breast cancer	2.07e-05	0.000166	CcSEcCtD
Dabigatran etexilate—Infection—Doxorubicin—breast cancer	2.06e-05	0.000166	CcSEcCtD
Dabigatran etexilate—Vomiting—Capecitabine—breast cancer	2.05e-05	0.000165	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Epirubicin—breast cancer	2.04e-05	0.000164	CcSEcCtD
Dabigatran etexilate—Shock—Doxorubicin—breast cancer	2.04e-05	0.000164	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Doxorubicin—breast cancer	2.03e-05	0.000164	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Doxorubicin—breast cancer	2.03e-05	0.000163	CcSEcCtD
Dabigatran etexilate—Rash—Capecitabine—breast cancer	2.03e-05	0.000163	CcSEcCtD
Dabigatran etexilate—Dermatitis—Capecitabine—breast cancer	2.03e-05	0.000163	CcSEcCtD
Dabigatran etexilate—Headache—Capecitabine—breast cancer	2.02e-05	0.000162	CcSEcCtD
Dabigatran etexilate—Skin disorder—Doxorubicin—breast cancer	2.01e-05	0.000162	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Epirubicin—breast cancer	2e-05	0.000161	CcSEcCtD
Dabigatran etexilate—Nausea—Docetaxel—breast cancer	1.97e-05	0.000159	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Epirubicin—breast cancer	1.97e-05	0.000159	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Methotrexate—breast cancer	1.96e-05	0.000158	CcSEcCtD
Dabigatran etexilate—Hypotension—Doxorubicin—breast cancer	1.94e-05	0.000156	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Epirubicin—breast cancer	1.94e-05	0.000156	CcSEcCtD
Dabigatran etexilate—Fatigue—Epirubicin—breast cancer	1.93e-05	0.000155	CcSEcCtD
Dabigatran etexilate—Constipation—Epirubicin—breast cancer	1.92e-05	0.000154	CcSEcCtD
Dabigatran etexilate—Nausea—Capecitabine—breast cancer	1.91e-05	0.000154	CcSEcCtD
Dabigatran etexilate—Urticaria—Methotrexate—breast cancer	1.9e-05	0.000153	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Methotrexate—breast cancer	1.89e-05	0.000152	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.89e-05	0.000152	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Doxorubicin—breast cancer	1.85e-05	0.000149	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Epirubicin—breast cancer	1.83e-05	0.000147	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Doxorubicin—breast cancer	1.83e-05	0.000147	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Doxorubicin—breast cancer	1.79e-05	0.000144	CcSEcCtD
Dabigatran etexilate—Fatigue—Doxorubicin—breast cancer	1.79e-05	0.000144	CcSEcCtD
Dabigatran etexilate—Urticaria—Epirubicin—breast cancer	1.78e-05	0.000143	CcSEcCtD
Dabigatran etexilate—Constipation—Doxorubicin—breast cancer	1.77e-05	0.000143	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Epirubicin—breast cancer	1.77e-05	0.000143	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Methotrexate—breast cancer	1.76e-05	0.000142	CcSEcCtD
Dabigatran etexilate—Asthenia—Methotrexate—breast cancer	1.72e-05	0.000138	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Doxorubicin—breast cancer	1.7e-05	0.000136	CcSEcCtD
Dabigatran etexilate—Pruritus—Methotrexate—breast cancer	1.69e-05	0.000136	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Epirubicin—breast cancer	1.65e-05	0.000133	CcSEcCtD
Dabigatran etexilate—Urticaria—Doxorubicin—breast cancer	1.65e-05	0.000133	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Doxorubicin—breast cancer	1.64e-05	0.000132	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Methotrexate—breast cancer	1.64e-05	0.000132	CcSEcCtD
Dabigatran etexilate—Asthenia—Epirubicin—breast cancer	1.61e-05	0.000129	CcSEcCtD
Dabigatran etexilate—Pruritus—Epirubicin—breast cancer	1.59e-05	0.000128	CcSEcCtD
Dabigatran etexilate—Dizziness—Methotrexate—breast cancer	1.58e-05	0.000127	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Epirubicin—breast cancer	1.53e-05	0.000123	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Doxorubicin—breast cancer	1.53e-05	0.000123	CcSEcCtD
Dabigatran etexilate—Vomiting—Methotrexate—breast cancer	1.52e-05	0.000122	CcSEcCtD
Dabigatran etexilate—Rash—Methotrexate—breast cancer	1.51e-05	0.000121	CcSEcCtD
Dabigatran etexilate—Dermatitis—Methotrexate—breast cancer	1.51e-05	0.000121	CcSEcCtD
Dabigatran etexilate—Headache—Methotrexate—breast cancer	1.5e-05	0.000121	CcSEcCtD
Dabigatran etexilate—Asthenia—Doxorubicin—breast cancer	1.49e-05	0.00012	CcSEcCtD
Dabigatran etexilate—Dizziness—Epirubicin—breast cancer	1.48e-05	0.000119	CcSEcCtD
Dabigatran etexilate—Pruritus—Doxorubicin—breast cancer	1.47e-05	0.000118	CcSEcCtD
Dabigatran etexilate—Vomiting—Epirubicin—breast cancer	1.43e-05	0.000115	CcSEcCtD
Dabigatran etexilate—Nausea—Methotrexate—breast cancer	1.42e-05	0.000114	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Doxorubicin—breast cancer	1.42e-05	0.000114	CcSEcCtD
Dabigatran etexilate—Rash—Epirubicin—breast cancer	1.41e-05	0.000114	CcSEcCtD
Dabigatran etexilate—Dermatitis—Epirubicin—breast cancer	1.41e-05	0.000114	CcSEcCtD
Dabigatran etexilate—Headache—Epirubicin—breast cancer	1.4e-05	0.000113	CcSEcCtD
Dabigatran etexilate—Dizziness—Doxorubicin—breast cancer	1.37e-05	0.00011	CcSEcCtD
Dabigatran etexilate—Nausea—Epirubicin—breast cancer	1.33e-05	0.000107	CcSEcCtD
Dabigatran etexilate—Vomiting—Doxorubicin—breast cancer	1.32e-05	0.000106	CcSEcCtD
Dabigatran etexilate—Rash—Doxorubicin—breast cancer	1.31e-05	0.000105	CcSEcCtD
Dabigatran etexilate—Dermatitis—Doxorubicin—breast cancer	1.31e-05	0.000105	CcSEcCtD
Dabigatran etexilate—Headache—Doxorubicin—breast cancer	1.3e-05	0.000104	CcSEcCtD
Dabigatran etexilate—Nausea—Doxorubicin—breast cancer	1.23e-05	9.91e-05	CcSEcCtD
Dabigatran etexilate—F2—Signaling Pathways—STK11—breast cancer	5.15e-06	5.83e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ADAM10—breast cancer	5.15e-06	5.83e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CTNNB1—breast cancer	5.13e-06	5.8e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—breast cancer	5.13e-06	5.8e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HADHB—breast cancer	5.1e-06	5.77e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GPI—breast cancer	5.1e-06	5.77e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PLG—breast cancer	5.09e-06	5.76e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC2A1—breast cancer	5.07e-06	5.74e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	5.07e-06	5.74e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP3A4—breast cancer	5.05e-06	5.71e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AKT2—breast cancer	5.04e-06	5.7e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ABCB1—breast cancer	5.03e-06	5.69e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	5.03e-06	5.69e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGF10—breast cancer	5.01e-06	5.67e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—breast cancer	4.99e-06	5.64e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—breast cancer	4.98e-06	5.63e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP1B1—breast cancer	4.97e-06	5.62e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TYMS—breast cancer	4.94e-06	5.59e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—breast cancer	4.94e-06	5.59e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PLA2G4A—breast cancer	4.89e-06	5.53e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NCOR1—breast cancer	4.89e-06	5.53e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTM1—breast cancer	4.89e-06	5.53e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—KRAS—breast cancer	4.88e-06	5.52e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—HSP90AA1—breast cancer	4.87e-06	5.51e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALDH7A1—breast cancer	4.87e-06	5.5e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALDH1A1—breast cancer	4.87e-06	5.5e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CD—breast cancer	4.84e-06	5.48e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PDGFA—breast cancer	4.84e-06	5.47e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—breast cancer	4.83e-06	5.46e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—breast cancer	4.82e-06	5.45e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TGFBR2—breast cancer	4.77e-06	5.39e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NCOA1—breast cancer	4.74e-06	5.36e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—breast cancer	4.71e-06	5.33e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ITPR1—breast cancer	4.69e-06	5.31e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GPX1—breast cancer	4.68e-06	5.29e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—STK11—breast cancer	4.67e-06	5.28e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP19A1—breast cancer	4.67e-06	5.28e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NME1—breast cancer	4.67e-06	5.28e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—FHL2—breast cancer	4.67e-06	5.28e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ADSL—breast cancer	4.67e-06	5.28e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PHGDH—breast cancer	4.67e-06	5.28e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—UMPS—breast cancer	4.67e-06	5.28e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MMP3—breast cancer	4.66e-06	5.27e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ERBB4—breast cancer	4.66e-06	5.27e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STAT5A—breast cancer	4.66e-06	5.27e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CB—breast cancer	4.65e-06	5.26e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—NCOA1—breast cancer	4.64e-06	5.25e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP1A1—breast cancer	4.63e-06	5.24e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ERCC2—breast cancer	4.59e-06	5.2e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—LDHB—breast cancer	4.58e-06	5.18e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—BRIP1—breast cancer	4.58e-06	5.18e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HPSE—breast cancer	4.58e-06	5.18e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—PLG—breast cancer	4.52e-06	5.12e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SMAD4—breast cancer	4.51e-06	5.1e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IGF1R—breast cancer	4.48e-06	5.07e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CA—breast cancer	4.48e-06	5.07e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—breast cancer	4.47e-06	5.05e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CXCL8—breast cancer	4.46e-06	5.05e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HES1—breast cancer	4.41e-06	4.98e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	4.38e-06	4.96e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PLA2G4A—breast cancer	4.38e-06	4.96e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NCOR1—breast cancer	4.38e-06	4.96e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—breast cancer	4.35e-06	4.92e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—COMT—breast cancer	4.34e-06	4.91e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HMMR—breast cancer	4.34e-06	4.91e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ABCC1—breast cancer	4.34e-06	4.91e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTA3—breast cancer	4.34e-06	4.91e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—breast cancer	4.34e-06	4.9e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CSF2—breast cancer	4.33e-06	4.9e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGF1—breast cancer	4.33e-06	4.9e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—RAF1—breast cancer	4.32e-06	4.89e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTP1—breast cancer	4.32e-06	4.89e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—MTHFR—breast cancer	4.32e-06	4.88e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NRG1—breast cancer	4.3e-06	4.86e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—H2AFX—breast cancer	4.27e-06	4.83e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—IL2—breast cancer	4.27e-06	4.83e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—HMOX1—breast cancer	4.26e-06	4.82e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ITPR1—breast cancer	4.25e-06	4.81e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—E2F1—breast cancer	4.24e-06	4.8e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CB—breast cancer	4.22e-06	4.77e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PPARGC1B—breast cancer	4.2e-06	4.75e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—HMOX1—breast cancer	4.17e-06	4.72e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—HRAS—breast cancer	4.15e-06	4.69e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—breast cancer	4.11e-06	4.65e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ABCB1—breast cancer	4.09e-06	4.63e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SPP1—breast cancer	4.07e-06	4.61e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CXCL8—breast cancer	4.05e-06	4.59e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ERBB3—breast cancer	4.03e-06	4.56e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGFR2—breast cancer	4.02e-06	4.55e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TYMS—breast cancer	4.02e-06	4.54e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—breast cancer	4e-06	4.53e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—breast cancer	3.99e-06	4.52e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CAV1—breast cancer	3.98e-06	4.51e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PLA2G4A—breast cancer	3.97e-06	4.49e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTM1—breast cancer	3.97e-06	4.49e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NCOR1—breast cancer	3.97e-06	4.49e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CA9—breast cancer	3.97e-06	4.49e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTA4—breast cancer	3.97e-06	4.49e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—breast cancer	3.91e-06	4.43e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL2—breast cancer	3.87e-06	4.38e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTA2—breast cancer	3.87e-06	4.37e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GPX2—breast cancer	3.87e-06	4.37e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TERT—breast cancer	3.86e-06	4.37e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SULT1A1—breast cancer	3.82e-06	4.32e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GPX4—breast cancer	3.82e-06	4.32e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GPX1—breast cancer	3.8e-06	4.3e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP1A1—breast cancer	3.76e-06	4.26e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGFR1—breast cancer	3.75e-06	4.24e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ERCC2—breast cancer	3.73e-06	4.22e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—IDH1—breast cancer	3.73e-06	4.22e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTA1—breast cancer	3.73e-06	4.22e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—breast cancer	3.73e-06	4.22e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CA—breast cancer	3.72e-06	4.21e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—breast cancer	3.7e-06	4.18e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HIF1A—breast cancer	3.69e-06	4.18e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NAT2—breast cancer	3.69e-06	4.17e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—AKT1—breast cancer	3.66e-06	4.14e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CG—breast cancer	3.63e-06	4.1e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—LEP—breast cancer	3.6e-06	4.08e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CAV1—breast cancer	3.57e-06	4.04e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KDR—breast cancer	3.53e-06	3.99e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—MTHFR—breast cancer	3.51e-06	3.97e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ESR1—breast cancer	3.44e-06	3.89e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FN1—breast cancer	3.4e-06	3.85e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—breast cancer	3.4e-06	3.84e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NFKBIA—breast cancer	3.36e-06	3.8e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOTCH1—breast cancer	3.33e-06	3.76e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—breast cancer	3.29e-06	3.72e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—APC—breast cancer	3.25e-06	3.68e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KIT—breast cancer	3.25e-06	3.68e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CG—breast cancer	3.25e-06	3.68e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CAV1—breast cancer	3.24e-06	3.66e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—DPYD—breast cancer	3.23e-06	3.66e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MED12—breast cancer	3.23e-06	3.66e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EGF—breast cancer	3.22e-06	3.64e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CD—breast cancer	3.19e-06	3.61e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALDOA—breast cancer	3.18e-06	3.6e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ALB—breast cancer	3.15e-06	3.56e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—MAPK3—breast cancer	3.12e-06	3.52e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.09e-06	3.5e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NCOA3—breast cancer	3.09e-06	3.5e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC2A2—breast cancer	3.07e-06	3.47e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—BRAF—breast cancer	3.06e-06	3.46e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AKT1—breast cancer	3.04e-06	3.44e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NOS3—breast cancer	3.01e-06	3.41e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CPT1A—breast cancer	3.01e-06	3.4e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ABCG2—breast cancer	3.01e-06	3.4e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MTR—breast cancer	3.01e-06	3.4e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IGF1—breast cancer	2.98e-06	3.37e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKT2—breast cancer	2.98e-06	3.37e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—EGFR—breast cancer	2.96e-06	3.35e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HPGDS—breast cancer	2.95e-06	3.34e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CG—breast cancer	2.95e-06	3.34e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HBA1—breast cancer	2.93e-06	3.31e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CD—breast cancer	2.86e-06	3.23e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTT1—breast cancer	2.86e-06	3.23e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ACHE—breast cancer	2.86e-06	3.23e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CA—breast cancer	2.83e-06	3.2e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SERPINE1—breast cancer	2.83e-06	3.2e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—KRAS—breast cancer	2.8e-06	3.17e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CB—breast cancer	2.78e-06	3.14e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—breast cancer	2.78e-06	3.14e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTGS2—breast cancer	2.75e-06	3.12e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP17A1—breast cancer	2.71e-06	3.06e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOS3—breast cancer	2.7e-06	3.05e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ENO1—breast cancer	2.68e-06	3.03e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS1—breast cancer	2.68e-06	3.03e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP2D6—breast cancer	2.63e-06	2.97e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CD—breast cancer	2.59e-06	2.93e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NCOA2—breast cancer	2.58e-06	2.92e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CA—breast cancer	2.57e-06	2.91e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MDM2—breast cancer	2.56e-06	2.9e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALB—breast cancer	2.56e-06	2.89e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RAF1—breast cancer	2.55e-06	2.89e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RELA—breast cancer	2.54e-06	2.88e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ERBB2—breast cancer	2.53e-06	2.86e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ALB—breast cancer	2.51e-06	2.83e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—FASN—breast cancer	2.5e-06	2.83e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CB—breast cancer	2.49e-06	2.82e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MTOR—breast cancer	2.49e-06	2.82e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—BCHE—breast cancer	2.49e-06	2.82e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC5A5—breast cancer	2.46e-06	2.78e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NOS3—breast cancer	2.45e-06	2.77e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTEN—breast cancer	2.4e-06	2.72e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCL8—breast cancer	2.4e-06	2.71e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—HRAS—breast cancer	2.38e-06	2.69e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC2A1—breast cancer	2.38e-06	2.69e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NQO1—breast cancer	2.38e-06	2.69e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1B—breast cancer	2.34e-06	2.65e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP3A4—breast cancer	2.32e-06	2.62e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AKT1—breast cancer	2.31e-06	2.62e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CASP3—breast cancer	2.29e-06	2.59e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL2—breast cancer	2.29e-06	2.59e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP1B1—breast cancer	2.28e-06	2.58e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL6—breast cancer	2.28e-06	2.58e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	2.27e-06	2.56e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CB—breast cancer	2.26e-06	2.56e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTGS2—breast cancer	2.24e-06	2.53e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HSP90AA1—breast cancer	2.23e-06	2.53e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCND1—breast cancer	2.23e-06	2.52e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—JUN—breast cancer	2.23e-06	2.52e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CTNNB1—breast cancer	2.21e-06	2.5e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NCOA1—breast cancer	2.17e-06	2.46e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MMP9—breast cancer	2.17e-06	2.45e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1A—breast cancer	2.16e-06	2.44e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTEN—breast cancer	2.15e-06	2.44e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—STK11—breast cancer	2.14e-06	2.42e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP19A1—breast cancer	2.14e-06	2.42e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAPK8—breast cancer	2.11e-06	2.38e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AKT1—breast cancer	2.1e-06	2.38e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SRC—breast cancer	2e-06	2.26e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—COMT—breast cancer	1.99e-06	2.25e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTP1—breast cancer	1.98e-06	2.24e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HMOX1—breast cancer	1.95e-06	2.21e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTEN—breast cancer	1.95e-06	2.21e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ITPR1—breast cancer	1.95e-06	2.21e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFA—breast cancer	1.95e-06	2.2e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STAT3—breast cancer	1.93e-06	2.18e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TYMS—breast cancer	1.84e-06	2.08e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAPK3—breast cancer	1.84e-06	2.08e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NCOR1—breast cancer	1.82e-06	2.06e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PLA2G4A—breast cancer	1.82e-06	2.06e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTM1—breast cancer	1.82e-06	2.06e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MYC—breast cancer	1.79e-06	2.02e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TGFB1—breast cancer	1.79e-06	2.02e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EGFR—breast cancer	1.75e-06	1.98e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GPX1—breast cancer	1.74e-06	1.97e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP1A1—breast cancer	1.73e-06	1.95e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ERCC2—breast cancer	1.71e-06	1.94e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CA—breast cancer	1.69e-06	1.92e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KRAS—breast cancer	1.65e-06	1.87e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MTHFR—breast cancer	1.61e-06	1.82e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CA—breast cancer	1.52e-06	1.72e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CAV1—breast cancer	1.48e-06	1.68e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—breast cancer	1.47e-06	1.66e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HRAS—breast cancer	1.41e-06	1.59e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AKT1—breast cancer	1.38e-06	1.57e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CA—breast cancer	1.38e-06	1.56e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CG—breast cancer	1.35e-06	1.53e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL6—breast cancer	1.35e-06	1.52e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKT1—breast cancer	1.24e-06	1.4e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CD—breast cancer	1.19e-06	1.34e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALB—breast cancer	1.17e-06	1.33e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AKT1—breast cancer	1.12e-06	1.27e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NOS3—breast cancer	1.12e-06	1.27e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CB—breast cancer	1.04e-06	1.17e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS2—breast cancer	1.03e-06	1.16e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTEN—breast cancer	8.95e-07	1.01e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CA—breast cancer	6.32e-07	7.15e-06	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AKT1—breast cancer	5.16e-07	5.84e-06	CbGpPWpGaD
